Center for Infectious Diseases and Vaccinology at Biodesign Institute, Arizona State University, Tempe, Arizona, USA.
Infect Immun. 2012 Feb;80(2):815-31. doi: 10.1128/IAI.05526-11. Epub 2011 Dec 5.
Live recombinant attenuated Salmonella vaccine (RASV) strains have great potential to induce protective immunity against Mycobacterium tuberculosis by delivering M. tuberculosis antigens. Recently, we reported that, in orally immunized mice, RASV strains delivering the M. tuberculosis early secreted antigenic target 6-kDa (ESAT-6) protein and culture filtrate protein 10 (CFP-10) antigens via the Salmonella type III secretion system (SopE amino-terminal region residues 1 to 80 with two copies of ESAT-6 and one copy of CFP-10 [SopE(Nt80)-E2C]) afforded protection against aerosol challenge with M. tuberculosis. Here, we constructed and evaluated an improved Salmonella vaccine against M. tuberculosis. We constructed translational fusions for the synthesis of two copies of ESAT-6 plus CFP-10 fused to the OmpC signal sequence (OmpC(SS)-E2C) and amino acids 44 to 338 of antigen 85A (Ag85A(294)) flanked by the signal sequence (SS) and C-terminal peptide (CT) of β-lactamase (Bla(SS)-Ag85A(294)-Bla(CT)) to enable delivery via the Salmonella type II secretion system. The genes expressing these proteins were cloned as an operon transcribed from P(trc) into isogenic Asd(+)/MurA(+) pYA3681 lysis vector derivatives with different replication origins (pBR, p15A, pSC101), resulting in pYA4890, pYA4891, and pYA4892 for SopE(Nt80)-E2C/Ag85A(294) synthesis and pYA4893 and pYA4894 for OmpC(SS)-E2C/Ag85A(294) synthesis. Mice orally immunized with the RASV χ11021 strain engineered to display regulated delayed lysis and regulated delayed antigen synthesis in vivo and harboring pYA4891, pYA4893, or pYA4894 elicited significantly greater humoral and cellular immune responses, and the RASV χ11021 strain afforded a greater degree of protection against M. tuberculosis aerosol challenge in mice than RASVs harboring any other Asd(+)/MurA(+) lysis plasmid and immunization with M. bovis BCG, demonstrating that RASV strains displaying regulated delayed lysis with delayed antigen synthesis resulted in highly immunogenic delivery vectors for oral vaccination against M. tuberculosis infection.
活重组减毒鼠伤寒沙门氏菌疫苗(RASV)株通过递呈结核分枝杆菌抗原,具有诱导针对结核分枝杆菌保护性免疫的巨大潜力。最近,我们报道了在口服免疫的小鼠中,通过沙门氏菌 III 型分泌系统(SopE 氨基端区域残基 1 至 80 位,带有两个 ESAT-6 拷贝和一个 CFP-10 拷贝[SopE(Nt80)-E2C])递送结核分枝杆菌早期分泌抗原靶 6kDa(ESAT-6)蛋白和培养滤液蛋白 10(CFP-10)抗原的 RASV 株可提供针对结核分枝杆菌气溶胶攻击的保护。在此,我们构建并评估了一种针对结核分枝杆菌的改良沙门氏菌疫苗。我们构建了翻译融合物,用于合成两个 ESAT-6 拷贝加 CFP-10 融合到 OmpC 信号序列(OmpC(SS)-E2C)和抗原 85A(Ag85A(294))的氨基酸 44 至 338,其侧翼是β-内酰胺酶(Bla(SS)-Ag85A(294)-Bla(CT))的信号序列(SS)和 C 端肽(CT),以通过沙门氏菌 II 型分泌系统进行递呈。表达这些蛋白的基因被克隆为一个操纵子,从 P(trc)转录,进入具有不同复制起点(pBR、p15A、pSC101)的同基因 Asd(+)/MurA(+)pYA3681 溶菌载体衍生物中,产生 pYA4890、pYA4891 和 pYA4892 用于 SopE(Nt80)-E2C/Ag85A(294)的合成,以及 pYA4893 和 pYA4894 用于 OmpC(SS)-E2C/Ag85A(294)的合成。用工程化的 RASV χ11021 菌株口服免疫小鼠,该菌株在体内显示调节延迟裂解和调节延迟抗原合成,并携带 pYA4891、pYA4893 或 pYA4894,可引起显著更强的体液和细胞免疫应答,并且 RASV χ11021 菌株在小鼠中提供了比携带任何其他 Asd(+)/MurA(+)溶菌质粒的 RASV 更大程度的保护,对抗结核分枝杆菌气溶胶攻击,用 M. bovis BCG 免疫接种,表明显示调节延迟裂解和延迟抗原合成的 RASV 株产生了针对结核分枝杆菌感染的高度免疫原性口服疫苗传递载体。